Single Oral Doses of ABX-1431 Demonstrate Statistically Significant Activity in Tourette Syndrome
SAN DIEGO, April 10, 2018 /PRNewswire/ -- Abide Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting the serine hydrolase family of enzymes, announced today its participation as part of the Emerging Science Data Blitz and Poster Session at the upcoming American Academy of Neurology (AAN) 70th Annual Meeting, to be held April 21 - 27, 2018, in Los Angeles, California. Details of the session are below.
Emerging Science Session: Tuesday, April 24, 2018. Data blitz presentation at 5:48 p.m., poster presentation to follow at 6:15 - 7:00 p.m. (PT).
This presentation provides further detail on previously announced results from the recently completed exploratory Phase 1b study in Tourette Syndrome (TS) with ABX-1431, a first-in-class investigational monoacylglycerol lipase (MGLL) inhibitor. In this randomized, double-blind, placebocontrolled crossover study in adults, patients receiving a single dose of ABX-1431 consistently showed a positive impact on key measures of TS symptoms. Abide believes these data are supportive of further advancement of ABX-1431 in TS and other movement disorders.
ABX-1431 is a first-in-class, small-molecule inhibitor of monoacylglycerol lipase (MGLL) for the treatment of neurological disorders. MGLL is a serine hydrolase which regulates one of the body's key natural activators of the cannabinoid receptors, 2-arachidonoylglycerol (2-AG), which signals through the cannabinoid receptors CB1 and CB2 to modulate neurotransmission and inflammatory signaling, respectively. Potent and selective inhibition of MGLL by ABX-1431 prevents the breakdown of 2-AG and amplifies cannabinoid receptor signaling in neural circuits, which are often dysregulated in disease states.
Direct cannabinoid receptor activation by cannabis derivatives and synthetic agonists has demonstrated clinical benefits in a number of central nervous system (CNS) diseases associated with overactive neurotransmission including spasticity associated with multiple sclerosis, chronic pain and Tourette syndrome. However, exocannabinoid use is limited by its broad activity and concomitant CNS adverse effects, and by challenges with administration and dosing precision. ABX-1431, as an oral therapy, provides the ability to modulate the endocannabinoid receptors selectively with the right dose in areas where circuits are activated, potentially increasing efficacy and limiting safety issues. The ability to safely correct aberrant neurotransmission suggests that ABX-1431 will have broad utility in a wide range of neurological diseases.
About Abide Therapeutics
Abide Therapeutics is focused on developing first-in-class drugs for serious diseases with significant unmet medical need. An innovative discovery platform and a library of proprietary small molecules allow Abide to address biological pathways with therapeutics that enhance the body's normal physiological response to disease. The platform enables Abide to efficiently identify, modify, and validate small-molecule inhibitors that target serine hydrolases, a highly relevant but under-explored class of enzymes. Abide's initial area of focus is on addressing neurological disorders with limited treatment options through the endocannabinoid pathway.
Abide has offices in San Diego, California and Princeton, New Jersey. To learn more, visit www.abidetx.com.
Tel: +1 619.244.2679
The Trout Group
Tel: +1 646.378.2942
SOURCE Abide Therapeutics
To read more Press Release articles, click here.